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The pill is not an abortive agent
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The original work by Pincus and Chang [1] on the 
effects of progesterone and related compounds has had 
a great impact on women’s fertility awareness. The 
birth of the ‘pilP has led to the use of oral contracep­
tives (OCs) by millions of women throughout the 
world. Eventually, changes in the dose and composition 
of the pill were necessary in order to minimize side 
effects. This has given rise to the development of the 
sub-50 pills (less than 50 meg of ethinylestradiol) and of 
various progestagens.
A different ‘side effect’ of the pill can also be noted 
when one opposes the use of the pill from a religious 
point of view [2]. It appears that one of the arguments 
increasingly heard from pro life organisations concerns 
the possible abortive action of OCs.
When contra-arguments exist for such action they 
have to be found in biological data on: (1) the working 
mechanism of OCs; (2) pregnancy during OC exposure; 
and (3) the morning after pill.
1. The working mechanism of OCs
The menstrual cycle is initiated and regulated by the 
hypothalamus and pituitary gland [3]. The hypothala­
mus activates the pituitary gland through luteinizing 
hormone releasing hormone (LHRH). The pituitary 
gland produces luteinizing hormone (LH) and follicle 
stimulating hormone (FSH).
FSH stimulates the growth of the ovarian follicles 
also called Graafian follicles containing the eggs. The 
granulosa cells of the follicle produce oestrogenic hor­
mones in increasing quantities. Due to these oestrogens 
LH is suddenly produced in a peak value. This results
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in ovulation and thereafter in corpus luteum formation, 
progesterone and oestrogen production.
The oestrogenic component of the oral contracep­
tives inhibits FSH release very strongly. This action 
induces the most important contraceptive property of 
OCs. The progestational component of the oral contra­
ceptive inhibits the LH-peak resulting in anovulation.
Ovarian follicles can be visualized with ultrasound 
techniques. During the use of low dose OCs ovarian 
follicles can be shown with a diameter of up to 18 mm 
[4,5], These follicles however, do not produce oestro­
gens and they can be considered as inactive. In addi­
tion, these follicles have a delayed growth and an LH 
peak is not observed. This can also be explained from 
the fact that the progestational component of all sub-50 
OCs induces a delay of the release of hypothalamic
LH-RH [6].
2. Pregnancy during OC exposure
OCs are reliable contraceptive agents. From prospec­
tive studies in which one or more pills were not taken at 
various moments of the ‘cycle5, one can conclude that 
the first and last days of the ‘cycle’ are crucial in 
allowing recovery of the gonadostat (hypothalamus and 
pituitary gland) or not. Such a recovery results in the 
initiation of the process of ovum maturation due to 
FSH and LH release,
Pregnancy is not only possible when pills are forgot­
ten, but it can also occur in women by regular and 
accurate pill use. In these women the bio-availability 
can be disturbed for instance by pathologic resorption 
in the gut, concomitant use of medication, or increased 
enzymatic metabolism. In all these instances pregnancy 
can occur despite pill exposure.
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After fertilization of the ovum a series of mitotic 
divisions occur. From the inner cell mass the embryo 
will develop. The outside blastomeres form the chori­
onic villi and placenta. The first product of these villi is 
the glycoprotein: human chorionic gonadotrophin 
(hCG) which is already produced before implantation. 
HCG has a strong stimulating action on the ovarian 
corpus luteum. This produces steroid hormones in in­
creasing amounts which in turn makes the en­
dometrium receptive for implantation during the so 
called decidual reaction. The effects of OCs on the 
endometrium can be summarized as: proliferative 
changes by oestrogens and secretory pseudodecidual 
changes through progestational agents.
In addition, the embryo itself has a strong hormonal 
signal function [7], thus making implantation possible 
during the use of OCs when an escape-ovulation oc­
curs. Endometrium is not even necessary for implanta­
tion when one observes ectopic pregnancies.
An early exposure of embryo and fetus to teratogenic 
effects of reproductive steroids only holds for the syn­
thetic stilbestrol or DES hormone and for masculiniz­
ing progestational agents with an androgenic action 
such as ethisterone and norethindrone. The currently 
available OCs do not have teratogenic or mutagenic 
action.
3. The morning after pill
An increased dose of reproductive steroids is used for 
postcoital contraception. This medication known as the 
morning after pill, is based on the observation in mon­
keys that reproductive steroids can interfere with ovum 
implantation and development [8]. One has to realize 
however that a placebo-randomised trial has never been 
performed in the human. The only way to distinguish 
myth from reality in postcoital contraception is to 
calculate statistical chances. Silvestre et al. [9] in analyz­
ing several studies on postcoital contraception have 
expressed serious doubt on the efficacy of the morning 
after pill.
In contrast, antiprogesterones (Mifepristone) are very 
effective as postcoital contraception [10].
It is clear that OCs are effective for contraception. It 
is also clear that the working mechanism of OCs con­
sists mainly of action on the hypothalamus/pituitary 
gland by inhibiting FSH and LH production and not 
primarily on the endometrium. Another argument for 
the non-abortive action of OCs is the fact that pregnan­
cies are observed during the irregular or even regular 
use of OCs. The embryo itself does have a strong 
signalling function permitting implantation. Even with­
out endometrium implantation is possible as seen in 
ectopic pregnancies.
No arguments can be found for an abortive action of 
OCs even when these are used in high doses. If one 
would oppose the use of OCs in general this can not be 
done with arguments of non-existing biological data.
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